Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

As of April 30, 2025, there are 82 publicly listed companies in China engaged in the in vitro diagnostics (IVD) industry. Among them, 61 companies focus primarily on IVD, while 21 have IVD as part of their broader business portfolios.

Grail has raised $300 million in a Series C financing round that wasoversubscribed, according to the firm.Ally Bridge Group led the round alongwith Hillhouse Capital Group and 6 Dimensions Capital. Blue Pool Capital, ChinaMerchant Securitie

Freenome has initiated a clinical study tohelp bring an AI-Genomics blood test for colorectal cancer to the U.S. market. Freenome is looking to build a diagnostictest that can learn from its mistakes. The South San Francisco, CA- basedcompa